Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults.
Journal
The Cochrane database of systematic reviews
ISSN: 1469-493X
Titre abrégé: Cochrane Database Syst Rev
Pays: England
ID NLM: 100909747
Informations de publication
Date de publication:
26 03 2021
26 03 2021
Historique:
entrez:
26
3
2021
pubmed:
27
3
2021
medline:
22
4
2021
Statut:
epublish
Résumé
Cardiovascular disease (CVD) is a major cause of disability and mortality globally. Premature fatal and non-fatal CVD is considered to be largely preventable through the control of risk factors by lifestyle modifications and preventive medication. Lipid-lowering and antihypertensive drug therapies for primary prevention are cost-effective in reducing CVD morbidity and mortality among high-risk people and are recommended by international guidelines. However, adherence to medication prescribed for the prevention of CVD can be poor. Approximately 9% of CVD cases in the EU are attributed to poor adherence to vascular medications. Low-cost, scalable interventions to improve adherence to medications for the primary prevention of CVD have potential to reduce morbidity, mortality and healthcare costs associated with CVD. To establish the effectiveness of interventions delivered by mobile phone to improve adherence to medication prescribed for the primary prevention of CVD in adults. We searched CENTRAL, MEDLINE, Embase, and two other databases on 7 January 2020. We also searched two clinical trials registers on 5 February 2020. We searched reference lists of relevant papers. We applied no language or date restrictions. We included randomised controlled trials investigating interventions delivered wholly or partly by mobile phones to improve adherence to cardiovascular medications prescribed for the primary prevention of CVD. We only included trials with a minimum of one-year follow-up in order that the outcome measures related to longer-term, sustained medication adherence behaviours and outcomes. Eligible comparators were usual care or control groups receiving no mobile phone-delivered component of the intervention. We used standard methodological procedures recommended by Cochrane. The main outcomes of interest were objective measures of medication adherence (blood pressure (BP) and cholesterol), CVD events, and adverse events. We contacted study authors for further information when this was not reported. We included 14 trials with 25,633 randomised participants. Participants were recruited from community-based primary and tertiary care or outpatient clinics. The interventions varied widely from those delivered solely through short messaging service (SMS) to those involving a combination of modes of delivery, such as SMS in addition to healthcare worker training, face-to-face counselling, electronic pillboxes, written materials, and home blood pressure monitors. Some interventions only targeted medication adherence, while others additionally targeted lifestyle changes such as diet and exercise. Due to heterogeneity in the nature and delivery of the interventions and study populations, we reported most results narratively, with the exception of two trials which were similar enough to meaningfully pool in meta-analyses. The body of evidence for the effect of mobile phone-based interventions on objective outcomes of adherence (BP and cholesterol) was of low certainty, due to most trials being at high risk of bias, and inconsistency in outcome effects. Two trials were at low risk of bias. Among five trials (total study enrolment: 5441 participants) recording low-density lipoprotein cholesterol (LDL-C), two studies found evidence for a small beneficial intervention effect on reducing LDL-C (-5.30 mg/dL, 95% confidence interval (CI) -8.30 to -2.30; and -9.20 mg/dL, 95% CI -17.70 to -0.70). The other three studies found results varying from a small reduction (-7.7 mg/dL) to a small increase in LDL-C (0.77 mg/dL). All of which had wide confidence intervals that included no effect. Across 13 studies (25,166 participants) measuring systolic blood pressure, effect estimates ranged from a large reduction (MD -12.45 mmHg, 95% CI -15.02 to -9.88) to a small increase (MD 2.80 mmHg, 95% CI 0.30 to 5.30). We found a similar range of effect estimates for diastolic BP, ranging from -12.23 mmHg (95% CI 14.03 to -10.43) to 1.64 mmHg (95% CI -0.55 to 3.83) (11 trials, 19,716 participants). Four trials showed intervention benefits for systolic and diastolic BP with confidence intervals excluding no effect, and among these were all three of the trials evaluating self-monitoring of blood pressure with mobile phone-based telemedicine. The fourth trial included SMS and provider support (with additional varied features). Seven studies (19,185 participants) reported 'controlled' BP as an outcome, and intervention effect estimates varied from negligible effects (odds ratio (OR) 1.01, 95% CI 0.76 to 1.34) to large improvements in BP control (OR 2.41, 95% CI: 1.57 to 3.68). The three trials of clinician training or decision support combined with SMS (with additional varied features) had confidence intervals encompassing benefits and harms, with point estimates close to zero. Pooled analyses of the two trials of interventions solely delivered through SMS were indicative of little or no beneficial intervention effect on systolic BP (MD -1.55 mmHg, 95% CI -3.36 to 0.25; I There is low-certainty evidence on the effects of mobile phone-delivered interventions to increase adherence to medication prescribed for the primary prevention of CVD. Trials of BP self-monitoring with mobile-phone telemedicine support reported modest benefits. One trial at low risk of bias reported modest reductions in LDL cholesterol but no benefits for BP. There is moderate-certainty evidence that these interventions do not result in harm. Further trials of these interventions are warranted.
Sections du résumé
BACKGROUND
Cardiovascular disease (CVD) is a major cause of disability and mortality globally. Premature fatal and non-fatal CVD is considered to be largely preventable through the control of risk factors by lifestyle modifications and preventive medication. Lipid-lowering and antihypertensive drug therapies for primary prevention are cost-effective in reducing CVD morbidity and mortality among high-risk people and are recommended by international guidelines. However, adherence to medication prescribed for the prevention of CVD can be poor. Approximately 9% of CVD cases in the EU are attributed to poor adherence to vascular medications. Low-cost, scalable interventions to improve adherence to medications for the primary prevention of CVD have potential to reduce morbidity, mortality and healthcare costs associated with CVD.
OBJECTIVES
To establish the effectiveness of interventions delivered by mobile phone to improve adherence to medication prescribed for the primary prevention of CVD in adults.
SEARCH METHODS
We searched CENTRAL, MEDLINE, Embase, and two other databases on 7 January 2020. We also searched two clinical trials registers on 5 February 2020. We searched reference lists of relevant papers. We applied no language or date restrictions.
SELECTION CRITERIA
We included randomised controlled trials investigating interventions delivered wholly or partly by mobile phones to improve adherence to cardiovascular medications prescribed for the primary prevention of CVD. We only included trials with a minimum of one-year follow-up in order that the outcome measures related to longer-term, sustained medication adherence behaviours and outcomes. Eligible comparators were usual care or control groups receiving no mobile phone-delivered component of the intervention.
DATA COLLECTION AND ANALYSIS
We used standard methodological procedures recommended by Cochrane. The main outcomes of interest were objective measures of medication adherence (blood pressure (BP) and cholesterol), CVD events, and adverse events. We contacted study authors for further information when this was not reported.
MAIN RESULTS
We included 14 trials with 25,633 randomised participants. Participants were recruited from community-based primary and tertiary care or outpatient clinics. The interventions varied widely from those delivered solely through short messaging service (SMS) to those involving a combination of modes of delivery, such as SMS in addition to healthcare worker training, face-to-face counselling, electronic pillboxes, written materials, and home blood pressure monitors. Some interventions only targeted medication adherence, while others additionally targeted lifestyle changes such as diet and exercise. Due to heterogeneity in the nature and delivery of the interventions and study populations, we reported most results narratively, with the exception of two trials which were similar enough to meaningfully pool in meta-analyses. The body of evidence for the effect of mobile phone-based interventions on objective outcomes of adherence (BP and cholesterol) was of low certainty, due to most trials being at high risk of bias, and inconsistency in outcome effects. Two trials were at low risk of bias. Among five trials (total study enrolment: 5441 participants) recording low-density lipoprotein cholesterol (LDL-C), two studies found evidence for a small beneficial intervention effect on reducing LDL-C (-5.30 mg/dL, 95% confidence interval (CI) -8.30 to -2.30; and -9.20 mg/dL, 95% CI -17.70 to -0.70). The other three studies found results varying from a small reduction (-7.7 mg/dL) to a small increase in LDL-C (0.77 mg/dL). All of which had wide confidence intervals that included no effect. Across 13 studies (25,166 participants) measuring systolic blood pressure, effect estimates ranged from a large reduction (MD -12.45 mmHg, 95% CI -15.02 to -9.88) to a small increase (MD 2.80 mmHg, 95% CI 0.30 to 5.30). We found a similar range of effect estimates for diastolic BP, ranging from -12.23 mmHg (95% CI 14.03 to -10.43) to 1.64 mmHg (95% CI -0.55 to 3.83) (11 trials, 19,716 participants). Four trials showed intervention benefits for systolic and diastolic BP with confidence intervals excluding no effect, and among these were all three of the trials evaluating self-monitoring of blood pressure with mobile phone-based telemedicine. The fourth trial included SMS and provider support (with additional varied features). Seven studies (19,185 participants) reported 'controlled' BP as an outcome, and intervention effect estimates varied from negligible effects (odds ratio (OR) 1.01, 95% CI 0.76 to 1.34) to large improvements in BP control (OR 2.41, 95% CI: 1.57 to 3.68). The three trials of clinician training or decision support combined with SMS (with additional varied features) had confidence intervals encompassing benefits and harms, with point estimates close to zero. Pooled analyses of the two trials of interventions solely delivered through SMS were indicative of little or no beneficial intervention effect on systolic BP (MD -1.55 mmHg, 95% CI -3.36 to 0.25; I
AUTHORS' CONCLUSIONS
There is low-certainty evidence on the effects of mobile phone-delivered interventions to increase adherence to medication prescribed for the primary prevention of CVD. Trials of BP self-monitoring with mobile-phone telemedicine support reported modest benefits. One trial at low risk of bias reported modest reductions in LDL cholesterol but no benefits for BP. There is moderate-certainty evidence that these interventions do not result in harm. Further trials of these interventions are warranted.
Identifiants
pubmed: 33769555
doi: 10.1002/14651858.CD012675.pub3
pmc: PMC8094419
doi:
Substances chimiques
Cholesterol, LDL
0
Banques de données
ClinicalTrials.gov
['NCT01834131', 'NCT03580330', 'NCT02913339', 'NCT01142908', 'NCT04120779', 'NCT03105687', 'NCT01890018', 'NCT04066010', 'NCT03515083', 'NCT03515681', 'NCT03872856', 'NCT03986931', 'NCT04076020', 'NCT04259489', 'NCT04409210', 'NCT03317951', 'NCT02377960', 'NCT03397849']
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
CD012675Commentaires et corrections
Type : UpdateOf
Type : CommentIn
Informations de copyright
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Références
Diabet Med. 2009 Jun;26(6):628-35
pubmed: 19538239
Am Heart J. 2016 Oct;180:90-7
pubmed: 27659887
JMIR Res Protoc. 2019 Mar 19;8(3):e11614
pubmed: 30888330
Telemed J E Health. 2012 Oct;18(8):613-20
pubmed: 23061642
Prog Cardiovasc Dis. 2020 Mar - Apr;63(2):125-133
pubmed: 32035124
Eur J Health Econ. 2013 Oct;14(5):789-97
pubmed: 22961230
BMC Cardiovasc Disord. 2015 Jan 19;15:8
pubmed: 25599690
Br J Gen Pract. 2019 Aug 29;69(686):e612-e620
pubmed: 31262847
Trials. 2014 Jan 24;15:36
pubmed: 24460845
Trials. 2020 Jun 16;21(1):530
pubmed: 32546189
Prog Transplant. 2015 Sep;25(3):217-23
pubmed: 26308780
Lancet. 2018 Nov 10;392(10159):1736-1788
pubmed: 30496103
J Hum Hypertens. 2015 Jul;29(7):436-41
pubmed: 25566874
JAMA Intern Med. 2013 Jan 14;173(1):38-43
pubmed: 23403978
Stud Health Technol Inform. 2012;178:228-34
pubmed: 22797046
Accid Anal Prev. 2014 Oct;71:311-8
pubmed: 24983189
Health Psychol. 2004 Mar;23(2):207-18
pubmed: 15008666
Trials. 2013 Jan 23;14:22
pubmed: 23343138
JMIR Res Protoc. 2017 Dec 19;6(12):e244
pubmed: 29258978
JMIR Res Protoc. 2019 Jan 25;8(1):e12601
pubmed: 30681965
J Gen Intern Med. 2015 Nov;30(11):1665-72
pubmed: 25952653
BMC Public Health. 2010 Feb 15;10:69
pubmed: 20156339
Eur J Prev Cardiol. 2014 Dec;21(12):1517-30
pubmed: 23990660
Hypertension. 2012 Jul;60(1):51-7
pubmed: 22615116
Blood Press. 2018 Apr;27(2):99-105
pubmed: 29172715
PLoS Med. 2009 Jul 21;6(7):e1000100
pubmed: 19621070
Trials. 2017 Jul 18;18(1):334
pubmed: 28720121
Telemed J E Health. 2011 May;17(4):254-61
pubmed: 21476945
JMIR Res Protoc. 2018 Nov 12;7(11):e11289
pubmed: 30425027
Contemp Clin Trials. 2020 Feb;89:105913
pubmed: 31838255
Trials. 2018 Feb 20;19(1):120
pubmed: 29458404
BMC Cardiovasc Disord. 2017 Feb 13;17(1):58
pubmed: 28193176
Contemp Clin Trials. 2012 Jul;33(4):794-803
pubmed: 22498720
Circulation. 2019 Jan 15;139(3):380-391
pubmed: 30586732
Curr Med Res Opin. 2019 Jan;35(1):167-173
pubmed: 30431384
J Acquir Immune Defic Syndr. 2015 Dec 15;70(5):495-502
pubmed: 26218411
JAMA. 2017 Sep 19;318(11):1016-1025
pubmed: 28975305
Ageing Int. 2011 Jun;36(2):159-191
pubmed: 21654869
J Am Heart Assoc. 2019 Apr 16;8(8):e011799
pubmed: 30943824
J Gen Intern Med. 2018 Sep;33(9):1536-1542
pubmed: 29546659
BMJ. 2016 Jun 28;353:i3305
pubmed: 27353261
Front Pharmacol. 2013 May 29;4:69
pubmed: 23755014
Diabetes Care. 2011 Feb;34(2):308-13
pubmed: 21270188
Soc Sci Med. 2005 Jul;61(1):133-55
pubmed: 15847968
JMIR Res Protoc. 2019 Apr 02;8(4):e11794
pubmed: 30938688
JMIR Mhealth Uhealth. 2018 Jul 13;6(7):e137
pubmed: 30006326
BMJ. 2009 May 19;338:b1665
pubmed: 19454737
AIDS. 2011 Mar 27;25(6):825-34
pubmed: 21252632
JMIR Mhealth Uhealth. 2020 Nov 2;8(11):e18922
pubmed: 33136059
Cochrane Database Syst Rev. 2017 Apr 29;4:CD011851
pubmed: 28455948
Bull World Health Organ. 2015 Dec 1;93(12):842-50A
pubmed: 26668436
Am J Prev Med. 2019 Jul;57(1):95-105
pubmed: 31128958
Am Heart J. 2018 May;199:122-129
pubmed: 29754649
Circ Cardiovasc Qual Outcomes. 2014 Mar;7(2):269-75
pubmed: 24619321
Lancet. 2012 Aug 11;380(9841):581-90
pubmed: 22607822
JAMA. 2013 Jul 3;310(1):46-56
pubmed: 23821088
BMJ Open. 2017 Aug 11;7(8):e014851
pubmed: 28801393
Am J Med. 2012 Sep;125(9):882-7.e1
pubmed: 22748400
Trials. 2018 Aug 7;19(1):429
pubmed: 30086778
BMJ. 2016 Jun 01;353:i2647
pubmed: 27252245
BMJ Open. 2016 Jun 03;6(6):e011306
pubmed: 27259530
Front Pharmacol. 2013 Jul 25;4:91
pubmed: 23898295
J Psychiatr Pract. 2009 Jan;15(1):34-44
pubmed: 19182563
Am J Manag Care. 2014 Nov;20(11 Spec No. 17):SP502-10
pubmed: 25811824
Am Heart J. 2012 Jun;163(6):980-6
pubmed: 22709750
J Adv Nurs. 2014 Sep;70(9):1932-1953
pubmed: 24689978
BMJ Open. 2020 Jan 6;10(1):e032734
pubmed: 31911516
Am Heart J. 2007 Jun;153(6):918-24
pubmed: 17540191
Br J Gen Pract. 2013 Nov;63(616):e768-76
pubmed: 24267860
Health Technol Assess. 2016 Jul;20(57):1-82
pubmed: 27483185
BMJ Open. 2016 Jun 10;6(6):e010806
pubmed: 27288376
Circ Cardiovasc Qual Outcomes. 2009 May;2(3):272-8
pubmed: 20031848
BMC Public Health. 2014 Jan 11;14:28
pubmed: 24410738
Glob Health Action. 2018;11(1):1517930
pubmed: 30253691
Eur Heart J. 2013 Oct;34(38):2940-8
pubmed: 23907142
Circulation. 2016 Feb 9;133(6):592-600
pubmed: 26769742
Cochrane Database Syst Rev. 2014 Nov 20;(11):CD000011
pubmed: 25412402
Circ Cardiovasc Qual Outcomes. 2021 May;14(5):e007015
pubmed: 33993727
BMC Res Notes. 2015 Mar 20;8:89
pubmed: 25888958
BMJ. 2013 May 24;346:f3030
pubmed: 23709583
Trials. 2020 Jun 3;21(1):456
pubmed: 32493502
BMJ Open. 2014 Jan 31;4(2):e004523
pubmed: 24486732
Diabet Med. 2016 May;33(5):565-79
pubmed: 26470750
JMIR Mhealth Uhealth. 2016 Jan 22;4(1):e10
pubmed: 26800712
Assist Technol. 2020;32(2):109-116
pubmed: 29944463
Int J Med Inform. 2012 Apr;81(4):257-69
pubmed: 22296762
BMJ Open. 2017 Jan 31;7(1):e014420
pubmed: 28143840
Transl Behav Med. 2020 Dec 31;10(6):1419-1435
pubmed: 31384950
J Acquir Immune Defic Syndr. 2015 Aug 15;69(5):551-9
pubmed: 25886927
BMC Cardiovasc Disord. 2009 Feb 16;9:6
pubmed: 19220913
Adv Biomed Res. 2015 Sep 28;4:204
pubmed: 26601092
Int J Environ Res Public Health. 2015 Dec 17;12(12):15993-6004
pubmed: 26694436
Lancet. 1990 Apr 7;335(8693):827-38
pubmed: 1969567
Rev Esp Cardiol (Engl Ed). 2018 Jan;71(1):33-41
pubmed: 28652127
Control Clin Trials. 2000 Feb;21(1):62-72
pubmed: 10660004
Trials. 2017 May 25;18(1):236
pubmed: 28545514
J Clin Pharm Ther. 2001 Oct;26(5):331-42
pubmed: 11679023
Cochrane Database Syst Rev. 2021 Mar 26;3:CD012675
pubmed: 33769555
Eur J Prev Cardiol. 2016 Jul;23(11):NP1-NP96
pubmed: 27353126
Ann Pharmacother. 2018 Nov;52(11):1098-1108
pubmed: 29808711
Acad Emerg Med. 2019 May;26(5):517-527
pubmed: 30659702
Med Care. 2014 Dec;52(12):1050-4
pubmed: 25322157
Contemp Clin Trials. 2007 Jul;28(4):459-71
pubmed: 17287150
J Clin Hypertens (Greenwich). 2019 Jan;21(1):29-36
pubmed: 30474909
Blood Press. 2020 Jun;29(3):149-156
pubmed: 31814476
Diabetes Care. 2014 Dec;37(12):3317-24
pubmed: 25315207
Lancet. 2018 Mar 10;391(10124):949-959
pubmed: 29499873
Contemp Clin Trials. 2020 Nov;98:106169
pubmed: 33038500
BMJ Open. 2020 Oct 16;10(10):e039447
pubmed: 33067295
IEEE Trans Inf Technol Biomed. 2008 Nov;12(6):780-91
pubmed: 19000959
Am Heart J. 2011 Feb;161(2):351-9
pubmed: 21315219
Lancet. 2010 Jul 17;376(9736):163-72
pubmed: 20619448
PLoS One. 2019 Mar 26;14(3):e0213708
pubmed: 30913216
Orthop Nurs. 2019 Sep/Oct;38(5):311-316
pubmed: 31568119
Patient Educ Couns. 2014 Feb;94(2):261-8
pubmed: 24321403
Int J Clin Pract. 2015 Jan;69(1):9-32
pubmed: 25472682
JAMA Intern Med. 2018 Sep 1;178(9):1182-1189
pubmed: 30083727
Scand J Prim Health Care. 2020 Jun;38(2):201-209
pubmed: 32362175
PLoS One. 2014 Dec 05;9(12):e114268
pubmed: 25479285
Lancet. 2010 Nov 27;376(9755):1838-45
pubmed: 21071074